Integrated Bioinformatics Approach for Disclosing Autophagy Pathway as a Therapeutic Target in Advanced KRAS Mutated/Positive Lung Adenocarcinoma

Background: Lung cancer is the leading cause of cancer-related deaths, accounting for 1.8 million deaths (18%). Nearly 80%-85% lung cases are non-small cell cancers (NSCLC). One most frequent genetic mutations in NSCLC Kirsten Rat Sarcoma Oncogene Homolog (KRAS) gene mutation. In recent years, autophagy has drawn substantial attention as a potential pathway that can be targeted driven by KRAS mutation to efficiently improve therapeutic profile different treatments. Methods: this study, we have investigated targeting treatment approach advanced KRAS-mutated adenocarcinoma using expression data from The Cancer Genome Atlas Adenocarcinoma (TCGA-LUAD) project. Results: Compared wild-type adenocarcinoma, there were found 11 differentially expressed autophagy-related genes (DEARGs), with 5 upregulated and 6 downregulated DEARGs (threshold adjusted p-value <0.05). Conclusion: These inhibitors.